Propiverine Hydrochloride
PreclinicalSmall molecule
Propiverine Hydrochloride is one of 18 small molecule programs targeting Stress urinary incontinence. It is currently in Preclinical.
2
Indications
5
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Interstitial Cystitis
#DrugCompanyPhaseTrials
1Toradol
RocheApproved
Revia
TevaApproved
Elavil
AstraZenecaApproved
Cellcept
RocheApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Pitocin
RRetrophin
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Neurontin
VViatris Specialty LLC
Approved
Elmiron
WWim Janssens
Approved
Neovasculgen
AArtgen Biotech
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Overactive Bladder3 trials
Stress urinary incontinence1 trial
Interstitial Cystitis1 trial
Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis
Completed·—·N/A·NCT03844581·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Propiverine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LLee's Pharmaceutical Limited